Treating Challenges as Opportunities

08/20/20 • 61 min

OIS Podcast | Ophthalmology's leading Podcast

This week, Firas Rahhal sat down (virtually) with none other than Mark Blumenkranz, who shares lessons learned the hard way which led to his proven “Innovation Recipe”. Mark also sheds light on the investing/incubating model for Lagunitas Biosciences and what he claims will be his final CEO role at Kedalion Therapeutics.

Previous Episode

Au Petit Bonheur La Chance

This week’s OIS Retina Podcast guest is French-born Patricia Zilliox, who boomeranged back to her homeland to become president and CEO of Eyevensys.
Before that she’d spent 25 years with Alcon before joining the Foundation Fighting Blindness as chief drug development officer.
When a family matter brought her back to France, she was introduced to Eyevensys through the investment group BPI France.
Having spent so much time evaluating new therapies at FFB, she was intrigued by Eyevensys’ unique platform to enable the sustained intraocular production of therapeutic proteins to treat a broad range of ophthalmic disease.
Needless to say, she took the CEO job and shares more details on Eyevensys’ lead product: a gene therapy to treat uveitis.

Next Episode

Listening to the Needs of the Customer

Seasoned start-up and medtech executive, Rob Thornhill joins us on this week’s OIS Podcast. Rob sold Tear Film to Alcon in 2018 and is back in the saddle as the CEO of Centricity Vision. Dr Sadri has Rob discuss the benefits of the Zepto device in delivering automated, precise, circular, and centered capsulotomies, how their business model evolved during COVID and the future direction for the company.